-157 - Table 1) . 
2) 나쁜 예후를 예상할 수 있는 미래 위험요소

1) 추적 폐 기능 검사에서 FEV1이 정상 이하로 나오는 경우
(1) 특히 FEV1 < 60% predicted이면 증상조절 정도와 상 관없이 급성 악화의 위험이 매우 높다 [7] .
Table 2. Risk fators for poor asthma outcomes
Assess risk factors at diagnosis and periodically, particularly for patients experiencing exacerbation. Measure FEV1 at start of treatment, after 3-6 months of controller treatment to record the patient's personal best lung function, then periodically for ongoing risk assessment.
Potentially modifiable independent risk factors for flare-ups (exacerbations)
Having one or more of these risk factors increases the risk of exacerbations even if symptoms are well controlled Uncontrolled asthma symptoms [7] Excessive SABA use (> 1 × 200-dose canister/month) [8] Inadequate ICS: not prescribed ICS; poor adherence [9] , incorrect inhaler technique [10] Low FEV1, especially if < 60% predicted [11] Major psychological or socioeconomic problens [12] Exposures: smoking [11] ; allergen exposure if sensitized [12] Comorbidities: obesity [13] ; rhinosinusitis [14] ; confirmed food allergy [15] Sputum or blood eosinophilia [16] Pregnancy [17] Other major independent risk factors for flare-ups (exacerbations)
Ever intubated or in intensive care unit for asthma [18] ≥ 1 severe exacerbation in last 12 months [19] Risk factors for developing fixed airflow limitation lack of ICS treatment [20] Exposures: tobacco smoke [21] ; noxious chemicals; occupational exposures Low initial FEV1 [22] ; chronic mucus hyperseveretion [22] ; sputum or blood eosinophilia [22] Risk factors for medication side-effects Systemic: frequent OCS; long-term, high dose and/or potent ICS; also taking P450 inhibitors [23] Local: high-dose or potent ICS [23] ; poor inhaler technique [24] ICS, inhaled glucocorticosteroid; OCS, oral corticosteroid.
(2) 증상 조절 정도와 상관없이 점차적으로 폐 기능이 감 소될 가능성이 있다 [22] . 2) 4단계 치료 3) 3단계 치료 2) 2단계 치료: 저용량 질병조절제와 증상 완화제 사용 중심 단어: 기관지 천식; 다양성; 폐기능검사
